<DOC>
	<DOCNO>NCT01173887</DOCNO>
	<brief_summary>This multicenter , randomize , open-label , parallel-group study compare mLSG15 + KW-0761 mLSG15 subject CCR4-positive adult T-cell leukemia-lymphoma ( untreated primary disease ) . The primary variable efficacy KW-0761 use add-on therapy mLSG15 measure term complete response rate ( CR/CRu ) best overall response assessment antitumor effect . The secondary variable include response rate ( CR/CRu/PR ) best overall response assessment antitumor effect , complete response rate lesion site best overall response assessment antitumor effect , progression-free survival overall survival . The safety pharmacokinetic profile KW-0761 also determine .</brief_summary>
	<brief_title>Multicenter , Randomized , Open-label , Parallel-group Study Compare mLSG15 + KW-0761 mLSG15</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<criteria>Subjects positive serum antihuman Tcell lymphotropic virus type I antibody Subjects hematologically pathohistologically confirm peripheral lymphoid tumor surface antigen analysis identify Tcell origin Subjects classify acute subtype , lymphoma subtype chronic subtype poor prognostic factor Subjects positive CCR4 CCR4 expression analysis Subjects never treat adult Tcell leukemialymphoma Subjects present enlarged lymph node , tumor nodule extranodal organ , abnormal lymphocytes peripheral blood cutaneous lesion Subjects performance status 0 2 Subjects negative HBs antigen antiHCV antibody Subjects give write voluntary inform consent participate study Subjects schedule transplant therapy hematopoietic stemcell transplantation Subjects myocardial infarction within 12 month study enrollment cardiac disease may worsen treatment doxorubicin Subjects positive antiHIV antibody Subjects active multiple cancer Subjects history allergic reaction therapeutic antibody Subjects require emergency radiotherapy treat symptom cause bulky mass may require radiotherapy start study Subjects pregnant , lactate childbearing potential , plan child</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>